Chronic myeloid leukemia following chemotherapy with 5'-deoxy-5-fluorouridine for gastric cancer

Intern Med. 2008;47(19):1739-41. doi: 10.2169/internalmedicine.47.1072. Epub 2008 Oct 1.

Abstract

We report here a very rare case of chronic myeloid leukemia (CML) following long-term chemotherapy with 5'-deoxy-5-fluorouridine (5'-DFUR) for gastric cancer. A 69-year-old man was diagnosed with the chronic phase of CML. Six years previously, he underwent radical subtotal gastrectomy for gastric cancer, and was subsequently treated with oral anti-metabolite 5'-DFUR as adjuvant chemotherapy for 6 years. He was placed on imatinib therapy, and achieved a major molecular response 10 months after the initiation of therapy. This is the first reported case of therapy-related CML following 5'-DFUR treatment.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Antimetabolites, Antineoplastic / adverse effects*
  • Chemotherapy, Adjuvant / adverse effects
  • Floxuridine / adverse effects*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / etiology*
  • Male
  • Neoplasms, Second Primary / etiology*
  • Stomach Neoplasms / drug therapy*
  • Time Factors

Substances

  • Antimetabolites, Antineoplastic
  • Floxuridine
  • doxifluridine